R. M. Sharpe
Research Subjects
Research Interests
R. M. Sharpe has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Chris McKinnell
MRC Human Reproductive Sciences Unit , Centre for Reproductive Biology, The Queen's Medical Research Institute , 47 Little France Crescent, Edinburgh EH16 4TJ , UK
2 shared publications C J H Kelnar
1 shared publicationC. McKINNELL
1 shared publicationD. Ganten
MDC, Berlin-Buch, 13122 Berlin, Germany
1 shared publicationD.L. Buchanan
1 shared publicationDriesche S van Den
1 shared publication
Latest Publications
- 1 March 2013
- Published by Bioscientifica in Endocrine Abstracts
- p. 1
Is diethylstilboestrol an endocrine disruptor in the developing human fetal testis? Effects of DES exposure using a xenograft approach
Context: In rodents, in-utero exposure to the exogenous oestrogen diethylstilboestrol (DES) results in reproductive abnormalities in male offspring. It has been proposed that similar anti-androgenic effects also occur in the human fetal testis following oestrogen exposure. Objective: Determine effects of DES exposure on testosterone production by normally growing human fetal testis xenografts. Design: Human fetal testes (15–19 weeks gestation, n=6) were xenografted into castrate male nude mice. Mice were treated for 35 days with vehicle or 100 μg/kg DES three times a week; all mice were treated with hCG to mimic normal human pregnancy. For comparison, fetal male rats were exposed in-utero to vehicle or 100 μg/kg DES on e13.5, e15.5, e17.5, e19.5 and e20.5. Main outcome measures: Testosterone production from xenografts was assessed by measuring host serum testosterone and seminal vesicle (SV) weights at termination. Insl3 production was determined in serum, whilst immunohistochemistry was performed for Insl3 and ERα. Results: Human fetal testis xenografts showed similar survival and total graft weight in DES and vehicle-exposed hosts. SV weight was significantly increased in DES compared to vehicle-exposed hosts (44.3 vs 26.6 mg, P=0.01) and testosterone was also increased (0.33 vs 0.45 ng/ml, P>0.05). There was no difference in Insl3 expression. In contrast, in-utero exposure of fetal rats to DES resulted in significantly lower intra-testicular testosterone levels associated with a reduction in Insl3 expression. ERα was expressed in fetal rat testis but was not expressed in the human fetal testis. Conclusions: Exposure of human fetal testes to DES does not impair testosterone production as it does in rats. This can be explained by a lack of ERα signalling in the human fetal testis. This highlights an important difference in the effect of proposed ‘endocrine disruptors’ in humans compared with rodents which has important implications for determining the risk posed to human health by environmental oestrogens. Declaration of funding: This work was supported by a BSPED Research award and an Academy of Medical Sciences Starter Grant for Clinical Lecturers.
- 1 March 2013
- Published by Bioscientifica in Endocrine Abstracts
- p. 1
Is diethylstilboestrol an endocrine disruptor in the developing human fetal testis? Effects of DES exposure using a xenograft approach
Context: In rodents, in-utero exposure to the exogenous oestrogen diethylstilboestrol (DES) results in reproductive abnormalities in male offspring. It has been proposed that similar anti-androgenic effects also occur in the human fetal testis following oestrogen exposure. Objective: Determine effects of DES exposure on testosterone production by normally growing human fetal testis xenografts. Design: Human fetal testes (15–19 weeks gestation, n=6) were xenografted into castrate male nude mice. Mice were treated for 35 days with vehicle or 100 μg/kg DES three times a week; all mice were treated with hCG to mimic normal human pregnancy. For comparison, fetal male rats were exposed in-utero to vehicle or 100 μg/kg DES on e13.5, e15.5, e17.5, e19.5 and e20.5. Main outcome measures: Testosterone production from xenografts was assessed by measuring host serum testosterone and seminal vesicle (SV) weights at termination. Insl3 production was determined in serum, whilst immunohistochemistry was performed for Insl3 and ERα. Results: Human fetal testis xenografts showed similar survival and total graft weight in DES and vehicle-exposed hosts. SV weight was significantly increased in DES compared to vehicle-exposed hosts (44.3 vs 26.6 mg, P=0.01) and testosterone was also increased (0.33 vs 0.45 ng/ml, P>0.05). There was no difference in Insl3 expression. In contrast, in-utero exposure of fetal rats to DES resulted in significantly lower intra-testicular testosterone levels associated with a reduction in Insl3 expression. ERα was expressed in fetal rat testis but was not expressed in the human fetal testis. Conclusions: Exposure of human fetal testes to DES does not impair testosterone production as it does in rats. This can be explained by a lack of ERα signalling in the human fetal testis. This highlights an important difference in the effect of proposed ‘endocrine disruptors’ in humans compared with rodents which has important implications for determining the risk posed to human health by environmental oestrogens. Declaration of funding: This work was supported by a BSPED Research award and an Academy of Medical Sciences Starter Grant for Clinical Lecturers.
- 2 January 1999
- Published by Wiley in Journal of Andrology
- Vol. 20 (1) , 94-101
Inhibin B Levels in Plasma of the Male Rat from Birth to Adulthood: Effect of Experimental Manipulation of Sertoli Cell Number
Sertoli cells undergo important changes in their number and function at different ages in the rat and may be the primary source of circulating inhibin B. The aims of this study were 1) to establish the profile of inhibin B levels from birth to adulthood in normal rats and 2) to identify whether experimental manipulation of Sertoli cell numbers was able to alter this profile. Levels of inhibin B, measured by a specific two‐site assay, increased fivefold in normal Wistar rats between day 3 and days 10–15, plateaued, and then declined in ate puberty to reach adult levels which were ∽60% of those observed on days 10–15. The increase in inhibin B levels in the neonatal period coincided with the period of Sertoli cell multiplication as indicated by incorporation of bromodeoxyuridine. Neonatal treatment of rats with a GnRH antagonist (GnRHa) reduced Sertoli cell number and adult testis weight by 48% and significantly reduced plasma levels of inhibin B at all ages through to adulthood. Induction of neonatal hypothyroidism in Sprague‐Dawley rats by administration of propylthiouracil (PTU) up to day 25 of age increased final testis weight by 41% (indicative of increased Sertoli cell numbers) and resulted in elevation of plasma levels of inhibin B at all ages beyond 7 days of age. The degree of change in inhibin B levels in adult rats in the two experimental treatment groups was approximately proportional to the change in final testis weight. Plasma follicle‐stimulating hormone (FSH) showed changes opposite to inhibin B, with levels being lowered in PTU‐treated rats and elevated (beyond day 25) in GnRHa‐treated animals. The present results suggest that final Sertoli cell number per testis exerts an important effect on the circulating level of inhibin B (and FSH) in the rat. These findings are compared to the emerging data for the human male.
- 2 January 1999
- Published by Wiley in Journal of Andrology
- Vol. 20 (1) , 94-101
Inhibin B Levels in Plasma of the Male Rat from Birth to Adulthood: Effect of Experimental Manipulation of Sertoli Cell Number
Sertoli cells undergo important changes in their number and function at different ages in the rat and may be the primary source of circulating inhibin B. The aims of this study were 1) to establish the profile of inhibin B levels from birth to adulthood in normal rats and 2) to identify whether experimental manipulation of Sertoli cell numbers was able to alter this profile. Levels of inhibin B, measured by a specific two‐site assay, increased fivefold in normal Wistar rats between day 3 and days 10–15, plateaued, and then declined in ate puberty to reach adult levels which were ∽60% of those observed on days 10–15. The increase in inhibin B levels in the neonatal period coincided with the period of Sertoli cell multiplication as indicated by incorporation of bromodeoxyuridine. Neonatal treatment of rats with a GnRH antagonist (GnRHa) reduced Sertoli cell number and adult testis weight by 48% and significantly reduced plasma levels of inhibin B at all ages through to adulthood. Induction of neonatal hypothyroidism in Sprague‐Dawley rats by administration of propylthiouracil (PTU) up to day 25 of age increased final testis weight by 41% (indicative of increased Sertoli cell numbers) and resulted in elevation of plasma levels of inhibin B at all ages beyond 7 days of age. The degree of change in inhibin B levels in adult rats in the two experimental treatment groups was approximately proportional to the change in final testis weight. Plasma follicle‐stimulating hormone (FSH) showed changes opposite to inhibin B, with levels being lowered in PTU‐treated rats and elevated (beyond day 25) in GnRHa‐treated animals. The present results suggest that final Sertoli cell number per testis exerts an important effect on the circulating level of inhibin B (and FSH) in the rat. These findings are compared to the emerging data for the human male.
- 1 June 1997
- Vol. 20 (3) , 171-9
Regulation of the secretion and synthesis of rat Sertoli cell SGP-1, SGP-2 and CP-2 by elongate spermatids.
The aim of this study was to investigate the effect of the absence of elongate spermatids (ES) from the rat seminiferous epithelium on the quantitative secretion and synthesis of the three major Sertoli cell secretory proteins--SGP-1, SGP-2 and CP-2. Seminiferous tubules (ST) were isolated (a) from normal 28-day-old rats, in which the most mature germ cell type is the round spermatid, (b) from normal adult rats at stages IX-XIV of the spermatogenic cycle, i.e. after spermiation, or at stages I-V and VI-VIII, when ES are still attached to the Sertoli cell, and (c) at stages VI-VIII from normal adult rats and from rats treated with methoxyacetic acid (MAA) in order to specifically deplete ES at these stages. Two-dimensional SDS PAGE combined with computerized image analysis was used to analyse 35S-methionine-labelled intracellular and secreted proteins. In the case of SGP-1 and SGP-2, almost all of the protein synthesized by ST was secreted. The total amount of both SGP-1 and CP-2 secreted by unstaged ST from immature rats was significantly lower than that secreted by unstaged ST from adult rats. The total amount of SGP-1 and CP-2 secreted by adult ST at stages IX-XIV of the spermatogenic cycle also declined dramatically compared to ST at earlier stages. The proportion of the total CP-2 synthesized by ST which was secreted also declined in all situations in which ES were absent from the seminiferous epithelium. The synthesis of only SGP-2 was changed by ES depletion from ST at stages VI-VIII, which was almost doubled compared to synthesis of this protein by ST from control rats. Our results suggest strongly that the secretion of SGP-1 and SGP-2 is via the constitutive pathway, and that regulation of these two proteins by ES is at the level of protein synthesis. In contrast, the regulation of CP-2 by ES is predominantly at the level of secretion, suggesting that this protein is secreted via a regulated pathway. Our findings add to the evidence showing that ES play a major role in the regulation of Sertoli cell function.
- 1 June 1997
- Vol. 20 (3) , 171-9
Regulation of the secretion and synthesis of rat Sertoli cell SGP-1, SGP-2 and CP-2 by elongate spermatids.
The aim of this study was to investigate the effect of the absence of elongate spermatids (ES) from the rat seminiferous epithelium on the quantitative secretion and synthesis of the three major Sertoli cell secretory proteins--SGP-1, SGP-2 and CP-2. Seminiferous tubules (ST) were isolated (a) from normal 28-day-old rats, in which the most mature germ cell type is the round spermatid, (b) from normal adult rats at stages IX-XIV of the spermatogenic cycle, i.e. after spermiation, or at stages I-V and VI-VIII, when ES are still attached to the Sertoli cell, and (c) at stages VI-VIII from normal adult rats and from rats treated with methoxyacetic acid (MAA) in order to specifically deplete ES at these stages. Two-dimensional SDS PAGE combined with computerized image analysis was used to analyse 35S-methionine-labelled intracellular and secreted proteins. In the case of SGP-1 and SGP-2, almost all of the protein synthesized by ST was secreted. The total amount of both SGP-1 and CP-2 secreted by unstaged ST from immature rats was significantly lower than that secreted by unstaged ST from adult rats. The total amount of SGP-1 and CP-2 secreted by adult ST at stages IX-XIV of the spermatogenic cycle also declined dramatically compared to ST at earlier stages. The proportion of the total CP-2 synthesized by ST which was secreted also declined in all situations in which ES were absent from the seminiferous epithelium. The synthesis of only SGP-2 was changed by ES depletion from ST at stages VI-VIII, which was almost doubled compared to synthesis of this protein by ST from control rats. Our results suggest strongly that the secretion of SGP-1 and SGP-2 is via the constitutive pathway, and that regulation of these two proteins by ES is at the level of protein synthesis. In contrast, the regulation of CP-2 by ES is predominantly at the level of secretion, suggesting that this protein is secreted via a regulated pathway. Our findings add to the evidence showing that ES play a major role in the regulation of Sertoli cell function.
- Open Access
- 1 August 1995
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 53 (2) , 214-226
Infertility in a Transgenic Rat Due to Impairment of Cytoplasmic Elimination and Sperm Release from the Sertoli Cells
In line TGR(mRen2)26 transgenic rats (TGR26) bearing a randomly inserted additional renin transgene, the males, but not the females, were found to be infertile. Tissue was obtained from TGR26 males and littermate controls after perfusion fixation, and the morphology of the testes and epididymides was examined. Testis size was normal as was gross morphology, but careful examination revealed that the release of many spermatozoa at stage IX of the spermatogenic cycle was impaired. In addition, the process of cytoplasmic elimination was abnormal, as cytoplasmic fragments of elongate spermatids were present in the epididymis. In TGR26 males, seminiferous tubule lumen size was significantly larger (p < 0.001) than in littermate controls, a difference that was most marked at stages IX-XIV—an effect that could be related to the retention of spermatozoa. In situ hybridization confirmed that expression of renin mRNA could be detected in testes of TGR26 rats but not in normal controls or in a fertile line (TGR27) of rats bearing the same transgene. Immunocytochemistry and in situ and Northern hybridization were used to elucidate the pattern of expression of genes that previous studies have implicated in the process of sperm maturation and/or release. Of the gene products examined (sulphated glycoproteins 1 and 2 [SGP-1, SGP-2], transition proteins 1 and 2 [TP-1, TP-2], urokinase, and cyclic protein 2 [CP-2]), none showed any major change in the pattern of expression compared with that in controls. We postulate that TGR26 transgenic male rats may be infertile because the expression of a gene (or genes) involved in the process of cytoplasmic elimination and/or sperm release has been disrupted by the presence of the transgene close to or within the gene(s). Future planned studies will involve determination of the insertion site(s) and ultrastructural analysis of the final phases of spermiogenesis.
- 1 August 1995
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 53 (2) , 214-226
Open AccessInfertility in a Transgenic Rat Due to Impairment of Cytoplasmic Elimination and Sperm Release from the Sertoli Cells
In line TGR(mRen2)26 transgenic rats (TGR26) bearing a randomly inserted additional renin transgene, the males, but not the females, were found to be infertile. Tissue was obtained from TGR26 males and littermate controls after perfusion fixation, and the morphology of the testes and epididymides was examined. Testis size was normal as was gross morphology, but careful examination revealed that the release of many spermatozoa at stage IX of the spermatogenic cycle was impaired. In addition, the process of cytoplasmic elimination was abnormal, as cytoplasmic fragments of elongate spermatids were present in the epididymis. In TGR26 males, seminiferous tubule lumen size was significantly larger (p < 0.001) than in littermate controls, a difference that was most marked at stages IX-XIV—an effect that could be related to the retention of spermatozoa. In situ hybridization confirmed that expression of renin mRNA could be detected in testes of TGR26 rats but not in normal controls or in a fertile line (TGR27) of rats bearing the same transgene. Immunocytochemistry and in situ and Northern hybridization were used to elucidate the pattern of expression of genes that previous studies have implicated in the process of sperm maturation and/or release. Of the gene products examined (sulphated glycoproteins 1 and 2 [SGP-1, SGP-2], transition proteins 1 and 2 [TP-1, TP-2], urokinase, and cyclic protein 2 [CP-2]), none showed any major change in the pattern of expression compared with that in controls. We postulate that TGR26 transgenic male rats may be infertile because the expression of a gene (or genes) involved in the process of cytoplasmic elimination and/or sperm release has been disrupted by the presence of the transgene close to or within the gene(s). Future planned studies will involve determination of the insertion site(s) and ultrastructural analysis of the final phases of spermiogenesis.